SNX 111

SNX-111 (also known as Ziconotide) is a synthetic form of a cone snail peptide, omega-conotoxin, used as a non-opioid analgesic. It is a selective N-type voltage-gated calcium channel blocker that has potent analgesic properties.

History

SNX-111 was first isolated from the venom of the marine cone snail species, Conus magus. The peptide was synthesized and developed into a drug by the pharmaceutical company Neurex, which was later acquired by Elan Corporation. The drug was approved by the FDA in 2004 under the brand name Prialt.

Mechanism of Action

SNX-111 works by blocking N-type voltage-gated calcium channels, which are primarily located in the pain transmitting neurons in the spinal cord. By blocking these channels, SNX-111 inhibits the release of pain neurotransmitters, thus providing analgesic effects.

Clinical Use

SNX-111 is used for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatments, such as systemic analgesics, adjunctive therapies, or IT morphine.

Side Effects

The most common side effects of SNX-111 include dizziness, nausea, confusion, and headache. Serious side effects may include hallucinations, severe mood changes, and difficulty with walking or coordination.

See Also

• Conotoxin
• Neurex
• Elan Corporation
• FDA